Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00593736 · ClinicalTrials.gov registry record · Phase 2

Efficacy of Ramelteon on Speeding Up Sleep in Subjects With Delayed Sleep Phase Syndrome

A Phase 2 study of Sleep Disorders, Circadian Rhythm, sponsored by Takeda.

Completed
Registry status
Phase 2
Development phase
132
Enrollment target
20
Study locations

NCT00593736 is a Phase 2 study of Sleep Disorders, Circadian Rhythm that has completed, run by Takeda. The registered enrollment target is 132 participants, above the 31-participant average among 4 other Sleep Disorders, Circadian Rhythm trials with a reported enrollment target (326% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00593736, a Phase 2 study of Sleep Disorders, Circadian Rhythm, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 2
Development phase
132 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the ability of ramelteon, once daily (QD), to advance the timing of sleep in individuals with delayed sleep phase syndrome.

Interventions

  • DRUG Placebo
  • DRUG Ramelteon

Study Locations (20)

Florida

  • - Hallandale Bch
  • - Naples
  • - Pembroke Pines
  • - South Miami
  • - Spring Hill
  • - St. Petersburg
  • - Winter Park

California

  • - Fountain Valley
  • - Glendale
  • - Los Angeles
  • - San Diego
  • - Santa Monica
  • - Tustin

Arkansas

  • - Hot Springs
  • - Little Rock

Georgia

  • - Atlanta
  • - Gainesville

Alabama

  • - Birmingham

Arizona

  • - Tucson

Colorado

  • - Colorado Springs

Trial Details

FieldValue
Enrollment Target 132 participants
Start Date 2007-10
Est. Completion 2008-05
Phase Phase 2

Sponsor

Takeda

408 total trials

What the Registry Record Tells You About NCT00593736

The ClinicalTrials.gov registry entry for NCT00593736 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 31-participant average among 4 other Sleep Disorders, Circadian Rhythm trials with a reported enrollment target (326% higher). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sleep Disorders, Circadian Rhythm appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00593736 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Arkansas.

Frequently Asked Questions

What is clinical trial NCT00593736 about?

NCT00593736 is a clinical study titled "Efficacy of Ramelteon on Speeding Up Sleep in Subjects With Delayed Sleep Phase Syndrome". The purpose of this study is to evaluate the ability of ramelteon, once daily (QD), to advance the timing of sleep in individuals with delayed sleep phase syndrome.

What is the current status of trial NCT00593736?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2007-10. Estimated completion is 2008-05.

What conditions does trial NCT00593736 study?

This clinical trial studies the following conditions: Sleep Disorders, Circadian Rhythm.

What interventions are being tested in trial NCT00593736?

The interventions under investigation include: Placebo (DRUG), Ramelteon (DRUG).

Who is sponsoring clinical trial NCT00593736?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00593736 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sleep Disorders, Circadian Rhythm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.